Incident adverse drug reactions in geriatric inpatients: a multicentred observational study. 2018

Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
Department of Medicine, University College Cork National University of Ireland, Cork, Ireland.

BACKGROUND Adverse drug reactions (ADRs) are common in older adults and frequently have serious clinical and economic consequences. This study was conducted as a feasibility study for a randomized control trial (RCT) that will investigate the efficacy of a software engine to optimize medications and reduce incident (in-hospital) ADRs. This study's objectives were to (i) establish current incident ADR rates across the six sites participating in the forthcoming RCT and (ii) assess whether incident ADRs are predictable. METHODS This was a multicentre, prospective observational study involving six European hospitals. Adults aged ⩾ 65 years, hospitalized with an acute illness and on pharmacological treatment for three or more conditions were eligible for inclusion. Adverse events (AEs) were captured using a trigger list of 12 common ADRs. An AE was deemed an ADR when its association with an administered drug was adjudicated as being probable/certain, according to the World Health Organization Uppsala Monitoring Centre causality assessment. The proportion of patients experiencing at least one, probable/certain, incident ADR within 14 days of enrolment/discharge was recorded. RESULTS A total of 644 patients were recruited, evenly split by sex and overwhelmingly of White ethnicity. Over 80% of admissions were medical. The median number of chronic conditions was five (interquartile range 4-6), with eight or more conditions present in approximately 10%. The mean number of prescribed medications was 9.9 (standard deviation 3.8), which correlated strongly with the number of conditions (r = 0.54, p < 0.0001). A total of 732 AEs were recorded in 382 patients, of which 363 were incident. The majority of events were classified as probably or possibly drug related, with heterogeneity across sites (χ2 = 88.567, df = 20, p value < 0.001). Out of 644 patients, 139 (21.6%; 95% confidence interval 18.5-25.0%) experienced an ADR. Serum electrolyte abnormalities were the most common ADR. The ADRROP (ADR Risk in Older People) and GerontoNet ADR risk scales correctly predicted ADR occurrence in 61% and 60% of patients, respectively. CONCLUSIONS This feasibility study established the rates of incident ADRs across the six study sites. The ADR predictive power of ADRROP and GerontoNet ADR risk scales were limited in this population.

UI MeSH Term Description Entries

Related Publications

Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
January 2003, Drugs & aging,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
June 1984, Archives of disease in childhood,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
February 2020, Geriatrics & gerontology international,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
January 2017, PloS one,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
August 2021, International journal of clinical pharmacy,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
May 2016, Indian journal of pediatrics,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
November 2015, Archives of dermatological research,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
November 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
May 2012, Clinics in geriatric medicine,
Amanda Lavan, and Joseph Eustace, and Darren Dahly, and Evelyn Flanagan, and Paul Gallagher, and Shane Cullinane, and Mirko Petrovic, and Katrina Perehudoff, and Adalsteinn Gudmondsson, and Ólafur Samuelsson, and Ástrós Sverrisdóttir, and Antonio Cherubin, and Frederica Dimitri, and Joe Rimland, and Alfonso Cruz-Jentoft, and Manuel Vélez-Díaz-Pallarés, and Isabel Lozano Montoya, and Roy L Soiza, and Selvarani Subbarayan, and Denis O'Mahony
October 1994, The Canadian journal of hospital pharmacy,
Copied contents to your clipboard!